Tocilizumab or TNF inhibitors in RA?

被引：3
|
作者：
Leake I. [1 ]
机构：
[1] Nature Reviews Rheumatology,
来源：
Nature Reviews Rheumatology | 2018年 / 14卷 / 7期
关键词：
D O I：
10.1038/s41584-018-0031-7
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：384 / 384
相关论文
共 50 条
  • [41] B-CELL MARKERS EXPRESSION IS AFFECTED BY TNF-INHIBITORS AND TOCILIZUMAB TREATMENT IN RHEUMATOID ARTHRITIS
    Moura, R. A.
    Quaresma, C.
    Vieira, A. R.
    Goncalves, M. J.
    Polido-Pereira, J.
    Romao, V.
    Martins, N.
    Canhao, H.
    Fonseca, J. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : A5 - A5
  • [42] Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors
    Kremer, J. M.
    Kvien, T. K.
    Tony, H.
    Tak, P. P.
    Luggen, M.
    Mariette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 40 - 40
  • [43] Efficacy of rituximab in active RA patients with an inadequate response toone or more TNF inhibitors
    Kremer, J. M.
    Maksymowych, W. P.
    Tony, H.
    Tak, P. P.
    Luggen, M.
    Mariette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1611 - 1611
  • [44] Guidelines in RA treatment: concepts on safety and recomendations using anti-TNF-α inhibitors
    Diaz-Jouanen, Efrain
    Abud-Mendoza, Carlos
    Alberto Garza-Elizondo, Mario
    Medrano-Ramirez, Gabriel
    Burgos-Vargas, Ruben
    Javier Orozco-Alcala, Jose
    Francisco Pacheco-Tena, Cesar
    Pineda, Carlos
    Pozos-Espindola, Juan Carlos
    Ramos-Niembro, Francisco
    Robles-San-Roman, Manuel
    Ernesto Santana-Sahagun, Jesus
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2009, 61 (03): : 252 - 266
  • [45] TNF Inhibitors Exert a "Hidden" Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients
    Calvo Alen, Jaime
    Alio Lavin-Gomez, Bernardo
    Aurrecoechea, Elena
    Guerra Ruiz, Armando Raul
    Martinez Taboada, Victor
    Gomez Gerique, Juan
    BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 187 - 197
  • [46] RHEUMATOID ARTHRITIS When TNF inhibitors fail in RA-weighing up the options
    Silva-Fernandez, Lucia
    Hyrich, Kimme
    NATURE REVIEWS RHEUMATOLOGY, 2014, 10 (05) : 262 - 264
  • [47] Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors
    Kremer, J. M.
    Tony, H.
    Tak, P. P.
    Luggen, M.
    Manette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 326 - 326
  • [48] TNF INHIBITORS ARE ASSOCIATED WITH A REDUCED RISK OF VENOUS THROMBOEMBOLISM COMPARED TO CSDMARDS IN RA PATIENTS
    Schaefer, M.
    Schneider, M.
    Graessler, A.
    Ochs, W.
    Zink, A.
    Strangfeld, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 8 - 9
  • [49] Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?
    Nocturne, Gaetane
    Seror, Raphaele
    Mariette, Xavier
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02)
  • [50] Autoantibodies and thrombophilia in RA:: TNFα and TNFα blockers
    Ferraccioli, GF
    Gremese, E
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (06) : 613 - 615
12345